Comstock Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Comstock Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.55M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $3.02M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.27M | Mar 6, 2025 |
| FY2018 | Dec 31, 2018 | $150.3K | Feb 26, 2019 |
| FY2017 | Dec 31, 2017 | $30.7K | Feb 20, 2018 |
| FY2017 | Sep 30, 2017 | $27.0K | Feb 20, 2018 |
| FY2017 | Jun 30, 2017 | $27.4K | Feb 20, 2018 |
| FY2017 | Mar 31, 2017 | $19.3K | Feb 20, 2018 |
| FY2017 | Dec 31, 2016 | $423.6K | Feb 20, 2018 |
| FY2017 | Sep 30, 2016 | $1.13M | Feb 20, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.27M | Feb 27, 2024 |
| FY2023 | Dec 31, 2022 | $178.2K | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $862.2K | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $201.7K | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $179.6K | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $150.3K | Mar 30, 2020 |
| FY2019 | Dec 31, 2017 | $104.3K | Mar 30, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $178.2K | Mar 16, 2023 |
| FY2022 | Dec 31, 2021 | $590.1K | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $149.8K | Mar 28, 2022 |
| FY2017 | Dec 31, 2017 | ($712.6K) | Feb 20, 2018 |
| FY2017 | Sep 30, 2017 | ($838.9K) | Feb 20, 2018 |
| FY2017 | Jun 30, 2017 | ($909.8K) | Feb 20, 2018 |
| FY2017 | Mar 31, 2017 | ($900.2K) | Feb 20, 2018 |
| FY2017 | Dec 31, 2016 | ($580.7K) | Feb 20, 2018 |
| FY2017 | Sep 30, 2016 | $273.9K | Feb 20, 2018 |
| FY2017 | Jun 30, 2016 | $136.6K | Feb 20, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($43.08M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($53.32M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $9.16M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($46.74M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($24.58M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $14.93M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($3.81M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($9.48M) | Mar 30, 2020 |
| FY2017 | Dec 31, 2017 | ($2.37M) | Feb 20, 2018 |
| FY2017 | Sep 30, 2017 | ($2.50M) | Feb 20, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($38.15M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($39.67M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($12.60M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($19.36M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($6.41M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($5.47M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($5.34M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($7.40M) | Mar 30, 2020 |
| FY2017 | Dec 31, 2017 | ($1.84M) | Feb 20, 2018 |
| FY2017 | Sep 30, 2017 | ($2.04M) | Feb 20, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.32M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $19.10M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $6.12M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $7.02M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $414.8K | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 28, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.67M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $12.70M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $12.59M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $10.24M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $5.55M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $4.40M | Mar 28, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.39M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($13.94M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($13.63M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($12.11M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($7.49M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($3.76M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($2.31M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($4.03M) | Mar 30, 2020 |
| FY2019 | Dec 31, 2017 | ($6.53M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | ($2.60M) | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $1.66M | Feb 26, 2019 |
| FY2018 | Dec 31, 2017 | $130.2K | Feb 26, 2019 |
| FY2018 | Dec 31, 2016 | $746.5K | Feb 26, 2019 |
| FY2017 | Dec 31, 2015 | $5.77M | Feb 20, 2018 |
| FY2016 | Dec 31, 2014 | $2.62M | Mar 9, 2017 |
| FY2015 | Dec 31, 2013 | $5.99M | Jan 28, 2016 |
| FY2014 | Dec 31, 2012 | $13.37M | Jan 29, 2015 |
| FY2013 | Dec 31, 2011 | $7.80M | Mar 21, 2014 |
| FY2012 | Dec 31, 2010 | $376.5K | Mar 18, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $169.60M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $91.31M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $106.47M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $100.05M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $126.95M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $43.12M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $39.57M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $28.61M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $30.96M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $33.84M | Feb 20, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.70M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $31.54M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $28.19M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $43.69M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $33.98M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $11.34M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $16.08M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $19.23M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $19.10M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $19.43M | Feb 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $107.58M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $59.77M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $78.28M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $53.60M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $89.57M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $31.78M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $23.22M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $9.38M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $11.87M | Feb 26, 2019 |
| FY2018 | Dec 31, 2016 | $14.42M | Feb 26, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.51M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 24, 2026 |
| FY2023 | Dec 31, 2022 | $0 | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | $12.79M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $0 | Mar 16, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($378.73M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($335.65M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($282.33M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($291.49M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($245.54M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($220.96M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($235.89M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($232.09M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($222.60M) | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($212.03M) | Feb 20, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.95M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $954.3K | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $3.79M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $2.52M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $5.91M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $2.43M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.02M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $488.7K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $2.07M | Feb 26, 2019 |
| FY2018 | Dec 31, 2016 | $184.4K | Feb 26, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $8.49M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $9.85M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $7.92M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $4.49M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $3.56M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $5.41M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $9.17M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $10.26M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $9.47M | Feb 20, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 10, 2021 |
| FY2017 | Dec 31, 2017 | 0 | Feb 20, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Feb 20, 2018 |
| FY2017 | Jun 30, 2017 | 0 | Feb 20, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 10, 2021 |
| FY2017 | Dec 31, 2017 | 0 | Feb 20, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Feb 20, 2018 |
| FY2017 | Jun 30, 2017 | 0 | Feb 20, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 51.85M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | 23.51M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | 11.79M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 91.44M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 71.21M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 34.98M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 27.24M | Mar 10, 2021 |
| FY2020 | Nov 29, 2019 | 25.39M | Mar 10, 2021 |
| FY2020 | Nov 28, 2019 | 126.97M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | 15.07M | Mar 30, 2020 |